Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05250362 | Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 56 | Sichuan UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04112589 | A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | unknown | Phase 1 / Phase 2 | 63 | PETHEMA FoundationOTHER | 1 |
| Mar 14, 2022 |
| clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04551235 | Establishing Automatic Method of Counting and Classify Bone Marrow and Peripheral Blood Cells | unknown | — | 900 | National Taiwan University HospitalOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) | unknown | Phase 1 | 20 | Seoul National University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | unknown | N/A | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT05186558 | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | unknown | Phase 2 | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT04893538 | Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma | unknown | — | 100 | Latakia UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262465 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML | unknown | N/A | 300 | guomeiOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04950777 | Feasibility and Efficacy of Physical Literacy Screening Integration Into Pediatric Clinical Settings(PLAY II) | unknown | N/A | 200 | Boston Children's HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05252572 | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05155839 | Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) | unknown | Phase 1 | 108 | Shanghai Miracogen Inc.INDUSTRY | 1 | Feb 22, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02776605 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia(PONALFIL) | unknown | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04253496 | Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)(LOC-MODEL) | unknown | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05239676 | Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | unknown | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05239689 | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies | unknown | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03529227 | Gazyva Infusion Reaction Investigation(GAIRI) | unknown | — | 104 | Healthy FutureOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Feb 14, 2022 | clinicaltrials |
| NCT05236621 | A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | unknown | Phase 3 | 85 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05233683 | Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children | unknown | Phase 3 | 120 | King Saud UniversityOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04273425 | Bone Pain in Multiple Myeloma- a Translational Study(BPMM) | unknown | — | 35 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT05223686 | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02575144 | GEM-CLARIDEX: Ld vs BiRd(GEM-CLARIDEX) | unknown | Phase 3 | 286 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03571997 | Study of Prognostic Factors in Adult Lymphoblastic Lymphoma | unknown | — | 30 | PETHEMA FoundationOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05052970 | Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | unknown | Phase 1 | 60 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | unknown | Early Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05206045 | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies(SURPASSe) | unknown | — | 700 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05206071 | Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05206903 | Emotional and Physical Health Status of Adults | unknown | — | 250 | Pamukkale UniversityOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05203809 | Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies(THERMAL) | unknown | — | 20 | Malaghan Institute of Medical ResearchOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05179850 | Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children | unknown | — | 400 | West China HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT01358201 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01366898 | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05137860 | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | unknown | Phase 4 | 56 | Hospital General de MexicoOTHER_GOV | 1 | Jan 18, 2022 | clinicaltrials |
| NCT04871165 | Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals | unknown | — | 3,270 | Vilnius UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05049083 | A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects | unknown | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05008575 | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03574454 | Machine Learning in Myeloma Response(MALIMAR) | unknown | N/A | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04384393 | Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05158608 | Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis(CY25) | unknown | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 0 | Jan 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2022source: clinicaltrials